Table 2.
Co‐morbidities of study participants stratified by OH status
| Co‐morbidity | No OH | COH | P | ISOH | IDOH | SDOH | COH | ISOH | IDOH | SDOH |
|---|---|---|---|---|---|---|---|---|---|---|
| % | % | % | % | % | Odds ratio (95% Confidence interval) | |||||
| Myocardial Infarction | 6.82 | 5.66 | .2426 | 4.74 | 8.47 | 5.17 | 0.82 (0.59‐1.15) | 0.68 (0.44‐1.06) | 1.27 (0.73‐2.19) | 0.75 (0.32‐1.72) |
| Stroke | 2.83 | 3.34 | .4459 | 2.47 | 5.08 | 4.31 | 1.19 (0.76‐1.86) | 0.87 (0.47‐1.61) | 1.84 (0.91‐3.72) | 1.55 (0.62‐3.89) |
| Atrial Fibrillation | 3.19 | 4.38 | .1044 | 2.07 | 9.09 | 6.90 | 1.39 (0.93‐2.07) | 0.64 (0.33‐1.24) | 3.04 (1.75‐5.27) | 2.25 (1.07‐4.74) |
| Diabetes mellitus | 5.75 | 6.04 | .7553 | 4.12 | 9.04 | 9.48 | 1.05 (0.76‐1.47) | 0.71 (0.44‐1.13) | 1.63 (0.95‐2.78) | 1.72 (0.91‐3.26) |
| Chronic kidney disease | 13.80 | 16.90 | .0281 | 16.12 | 15.91 | 21.74 | 1.27 (1.03‐1.57) | 1.20 (0.92‐1.56) | 1.18 (0.78‐1.79) | 1.74 (1.10‐2.74) |
| Antihypertensive medication use | 30.02 | 35.09 | .0064 | 35.46 | 33.33 | 36.21 | 1.26 (1.07‐1.49) | 1.28 (1.05‐1.57) | 1.17 (0.85‐1.61) | 1.32 (0.90‐1.95) |
| Chronic obstructive pulmonary disease | 25.10 | 31.91 | .0001 | 33.06 | 28.00 | 33.04 | 1.4 (1.18‐1.66) | 1.47 (1.20‐1.81) | 1.16 (0.83‐1.63) | 1.47 (0.99‐2.19) |
| Hypertension | 72.43 | 87.15 | <.0001 | 84.95 | 90.40 | 91.38 | 2.58 (2.06‐3.23) | 2.15 (1.66‐2.79) | 3.58 (2.16‐5.94) | 4.04 (2.10‐7.76) |
Abbreviations: COH, consensus orthostatic hypotension (n = 778); IDOH—isolated diastolic orthostatic hypotension (n = 177); ISOH, isolated systolic orthostatic hypotension (n = 485); No OH (n = 3079); SDOH—combined systolic and diastolic orthostatic hypotension (n = 116).
The odds ratios are unadjusted and compare the odds of co‐morbidity among participants with OH, or its components, to those without OH.